Vincent A.
- Country
- France
- Department
- Service de Néphrologie et Transplantation
Research Overview
- A multicenter randomized trial to evaluate the efficacy of pioglitazone to promote renal tolerance in ANCA-associated vasculitis - RENATO
- Efficacy and Safety of Oral BI 764198 in Adults and Adolescents with Primary or TRPC6-Variant Genetic Focal Segmental Glomerulosclerosis: A Randomized, Placebo-Controlled Trial
- Efficacy and Safety of Obinutuzumab Versus Glucocorticoid Therapy in Adults with De Novo Minimal Change Disease: A Phase IIa Randomized Controlled Trial
Data & Insights
Has run more than one trial at 129 of 285 partner sites.
Specializations
Kidney Disease Management
This investigator specializes in various forms of proteinuric kidney diseases, with particular focus on APOL1-mediated kidney disease and focal segmental glomerulosclerosis. Their research extends to innovative treatments for membranous nephropathy and investigation of artificial intelligence-based treatment protocols.
- Proteinuria Management
- Glomerular Diseases
- AI-Based Treatment Protocols
Autoimmune Conditions
The investigator has significant expertise in treating ANCA-associated vasculitis and granulomatosis with polyangiitis. Their work includes evaluation of novel therapeutic approaches for minimal change nephrotic syndrome and investigation of targeted immunological treatments.
- Vasculitis Treatment
- Immunosuppressive Therapies
- Nephrotic Syndrome Management
Specialized Therapeutic Areas
Research interests encompass IgA nephropathy and childhood idiopathic nephrotic syndrome. The investigator also studies sickle cell disease complications and their impact on organ function, particularly focusing on innovative therapeutic approaches.
- Pediatric Nephrology
- Hematological Disorders
- Novel Drug Development
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.